Evidence-Based Guide

Shingrix Vaccine Guide: Who Needs It, Effectiveness, Side Effects, and Timing

A physician-reviewed 2026 guide to Shingrix recommendations, dosing, effectiveness, side effects, contraindications, coverage, and the end of Zostavax.

Medically reviewed by Parth Bhavsar, MDLast reviewed August 10, 202611 min read
A physician-reviewed 2026 guide to Shingrix recommendations, dosing, effectiveness, side effects, contraindications, coverage, and the end of Zostavax.

Who should get Shingrix, and how effective is the shingles vaccine?

Shingrix is the preferred U.S. shingles vaccine for immunocompetent adults age 50 and older and immunocompromised adults age 19 and older. It is a two-dose, non-live vaccine. Pivotal trials found 97.2% efficacy against shingles in adults age 50 and older and 91.3% in pooled adults age 70 and older. ACIP guidance and the ZOE-50 trial provide the core evidence.
Medically reviewed by Parth Bhavsar, MD. Updated August 10, 2026.

Key Takeaways

  • Shingrix is a non-live, two-dose vaccine preferred over the discontinued live vaccine. [3]
  • Adults age 50+ and immunocompromised adults age 19+ are eligible under ACIP recommendations. [3][4]
  • The standard dose interval is 2 to 6 months, with a 1 to 2 month option for some immunocompromised adults. [4]
  • Trial efficacy was 97.2% in adults age 50+ and 91.3% in adults age 70+. [1][2]
  • A sore arm and short-term systemic reactions are common; completing both doses matters. [1]
  • Coverage is plan-specific, so confirm your cost with the insurer or pharmacy.

For general shingles diagnosis, treatment, and the 72-hour window, see the complete shingles guide.

What Is Shingrix?

Shingrix is a recombinant, adjuvanted zoster vaccine. It is not a live vaccine. Its purpose is to prevent shingles and its complications, especially postherpetic neuralgia. ACIP prefers it over the older live zoster vaccine for eligible adults. [3][8]

Who Should Get the Shingles Vaccine?

ACIP recommends two Shingrix doses for immunocompetent adults age 50 and older. In 2022, ACIP expanded use to immunocompromised adults age 19 and older because shingles can be more frequent and severe in these groups. [3][4]

How Effective Is Shingrix?

The ZOE-50 trial found 97.2% vaccine efficacy against shingles in adults age 50 and older. In ZOE-70, pooled efficacy in adults age 70 and older was 91.3%, and efficacy against PHN was 88.8% in that age group. [1][2]

Shingrix efficacy in pivotal trialsVaccine efficacy against shingles or postherpetic neuralgia0%25%50%75%100%97.2%91.3%88.8%Adults 50+Adults 70+PHN, adults 70+

Trial results are estimates from the ZOE-50 and ZOE-70 studies.[1][2]

Shingrix Dosing Schedule

The standard series is two doses, 2 to 6 months apart. For immunocompromised adults and others who need a shorter schedule, the second dose may be given 1 to 2 months after the first. A clinician can help choose timing around immune-suppressing treatment. [3][4]

Shingrix is a two-dose seriesStandard timing and shorter timing option for immunocompromised adultsDose 1Dose 2Today2 to 6 months laterShorter option: 1 to 2 months later

The shortened interval is for immunocompromised adults who would benefit from completing the series sooner.[3][4]

SituationTwo-dose timingClinical note
Most adults age 50+Dose 2 at 2 to 6 monthsComplete both doses for the studied series.
Immunocompromised adults age 19+Dose 2 at 1 to 2 months when a shorter schedule is neededPlan timing with the clinician managing immune-suppressing treatment.
Prior shingles or ZostavaxStill a two-dose Shingrix series if eligibleDo not vaccinate during an acute shingles episode.

Safety and Expected Side Effects

Local and systemic reactions are common. In ZOE-50, 81.5% of vaccine recipients reported injection-site reactions and 46.3% reported myalgia; 96% completed both doses despite reactogenicity. These effects usually resolve within a few days. [1]

Common reactionWhat to expectWhen to seek advice
Sore arm, redness, swellingUsually short-lived after the injectionCall for signs of a severe allergic reaction.
Muscle aches, fatigue, headache, feverishnessCan affect plans for one or two daysSeek urgent care for trouble breathing, facial swelling, or hives.
Stomach symptomsLess common and usually temporaryContact a clinician if severe or persistent.

Shingrix in Immunocompromised Adults

Evidence and ACIP guidance support Shingrix in immunocompromised adults age 19 and older. A phase 3 study also evaluated immunogenicity and safety in adults with hematologic malignancies. Timing can depend on chemotherapy, transplant, or other immune-suppressing therapy, so care should be coordinated with the treating team. [4][5]

Shingrix Compared With Zostavax

Zostavax was a live zoster vaccine. Shingrix is non-live and became the preferred U.S. option because of substantially higher efficacy. Zostavax was discontinued in the United States in November 2020. People who previously received it may still be eligible for Shingrix. [3][8]

Cost, Coverage, and Contraindications

Coverage varies. Confirm whether a plan uses a pharmacy benefit, medical benefit, deductible, or preferred pharmacy. Shingrix should not be used in someone with a severe allergy to a component or a prior dose. It is generally deferred during active shingles or a moderate to severe acute illness. [3][4]

Frequently Asked Questions

ACIP recommends Shingrix for immunocompetent adults age 50 and older and immunocompromised adults age 19 and older.
Two doses are needed. Most people receive dose two 2 to 6 months after dose one. Immunocompromised adults who would benefit from a shorter schedule can receive the second dose 1 to 2 months after the first.
Yes. Prior shingles does not remove the recommendation for eligible adults. Do not receive Shingrix during an acute shingles episode.
Yes. Shingrix is recommended for eligible adults regardless of prior Zostavax. Zostavax is no longer used in the United States.
In pivotal trials, Shingrix efficacy against shingles was 97.2% in adults age 50 and older and 91.3% in pooled adults age 70 and older.
Sore arm, redness, swelling, fatigue, muscle aches, headache, feverishness, and stomach symptoms can occur. These reactions are usually short-lived.
People with a severe allergy to a vaccine component or prior dose should not receive it. Vaccination is usually deferred during a current shingles episode or moderate to severe acute illness.
Coverage and out-of-pocket costs differ by plan, pharmacy, age, and whether the dose is billed under a pharmacy or medical benefit. Confirm the price with the insurer or pharmacy before vaccination.
Shingrix is a recombinant, non-live vaccine. It cannot cause a shingles infection.

Evidence used in this guide: [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17]

References

  1. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine. 2015;372:2087-2096. PMID: 25916341. https://pubmed.ncbi.nlm.nih.gov/25916341/
  2. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine. 2016;375:1019-1032. PMID: 27626517. https://pubmed.ncbi.nlm.nih.gov/27626517/
  3. Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018;67:103-108. PMID: 29370152. https://pubmed.ncbi.nlm.nih.gov/29370152/
  4. Anderson TC, Masters NB, Guo A, et al. Use of recombinant zoster vaccine in immunocompromised adults aged 19 years: recommendations of ACIP. MMWR. 2022;71:80-84. PMID: 35051134. https://pubmed.ncbi.nlm.nih.gov/35051134/
  5. Dagnew AF, Ilhan O, Lee WS, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies. Lancet Infectious Diseases. 2019;19:988-1000. PMID: 31399377. https://pubmed.ncbi.nlm.nih.gov/31399377/
  6. Strezova A, Diez-Domingo J, Al Shawafi K, et al. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: results up to 10 years after initial vaccination. Open Forum Infectious Diseases. 2022;9:ofac485. PMID: 36299530. https://pubmed.ncbi.nlm.nih.gov/36299530/
  7. Strezova A, et al. Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications. EClinicalMedicine. 2025. PMID: 40630610. https://pubmed.ncbi.nlm.nih.gov/40630610/
  8. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine. 2005;352:2271-2284. PMID: 15930418. https://pubmed.ncbi.nlm.nih.gov/15930418/
  9. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833. PMID: 24916088. https://pubmed.ncbi.nlm.nih.gov/24916088/
  10. Opstelten W, Zaal MJ. Managing ophthalmic herpes zoster in primary care. BMJ. 2005;331:147-151. PMID: 16020856. https://pubmed.ncbi.nlm.nih.gov/16020856/
  11. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837-1842. PMID: 9846778. https://pubmed.ncbi.nlm.nih.gov/9846778/
  12. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrobial Agents and Chemotherapy. 1995;39:1546-1553. PMID: 7492102. https://pubmed.ncbi.nlm.nih.gov/7492102/
  13. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. Annals of Internal Medicine. 1995;123:89-96. PMID: 7778840. https://pubmed.ncbi.nlm.nih.gov/7778840/
  14. Cobo LM, Foulks GN, Liesegang T, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology. 1986;93:763-770. PMID: 3488532. https://pubmed.ncbi.nlm.nih.gov/3488532/
  15. Yawn BP, Wollan PC, St Sauver JL, Butterfield LC. Herpes zoster eye complications: rates and trends. Mayo Clinic Proceedings. 2013;88:562-570. PMID: 23664666. https://pubmed.ncbi.nlm.nih.gov/23664666/
  16. Hempenstall K, Nurmikko TJ, Johnson RW, A’Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Medicine. 2005;2:e164. PMID: 16013891. https://pubmed.ncbi.nlm.nih.gov/16013891/
  17. Dworkin RH, Johnson RW, Breuer J, et al. Treatment and prevention of postherpetic neuralgia. Clinical Infectious Diseases. 2003;36:877-882. PMID: 12652389. https://pubmed.ncbi.nlm.nih.gov/12652389/

About the Author

Parth Bhavsar, MD is a board-certified family medicine physician and founder of TeleDirectMD. His editorial work focuses on practical, evidence-based guidance for common acute and chronic conditions.

All content on this page reflects the cited evidence and was last reviewed August 10, 2026.